WO2000006204A3 - Cellules genetiquement modifiees et tissus - Google Patents

Cellules genetiquement modifiees et tissus Download PDF

Info

Publication number
WO2000006204A3
WO2000006204A3 PCT/US1999/016961 US9916961W WO0006204A3 WO 2000006204 A3 WO2000006204 A3 WO 2000006204A3 US 9916961 W US9916961 W US 9916961W WO 0006204 A3 WO0006204 A3 WO 0006204A3
Authority
WO
WIPO (PCT)
Prior art keywords
genetically engineered
tissues
stimulus
express
response
Prior art date
Application number
PCT/US1999/016961
Other languages
English (en)
Other versions
WO2000006204A2 (fr
Inventor
Gail K Naughton
Jonathon N Mansbridge
Original Assignee
Advanced Tissue Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Tissue Sciences Inc filed Critical Advanced Tissue Sciences Inc
Priority to KR1020017001189A priority Critical patent/KR20010085313A/ko
Priority to EP99938808A priority patent/EP1100548A2/fr
Priority to AU53212/99A priority patent/AU5321299A/en
Priority to JP2000562057A priority patent/JP2002521046A/ja
Priority to CA002338487A priority patent/CA2338487A1/fr
Publication of WO2000006204A2 publication Critical patent/WO2000006204A2/fr
Publication of WO2000006204A3 publication Critical patent/WO2000006204A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des cellules génétiquement modifies capables d'exprimer un gène cible en réponse à un 'signal environnemental' ou à un 'stimulus', ainsi que leur utilisation pour la production de tissus tridimensionnels ou de préparations injectables pour la réparation, le remplacement ou l'amélioration de tissus, et pour l'administration de thérapies géniques in vivo. En particulier, cette invention concerne des bioréacteurs cellulaires et tissulaires conçus pour exprimer un produit génique cible qui renseigne sur un état physiologique déterminé, accentue l'expression déficiente ou défectueuse du produit génique ou déploie une activité anti-virale, anti-bactérienne, anti-microbienne ou anti-cancéreuse en réponse à un 'signal environnemental' ou à un 'stimulus' donné.
PCT/US1999/016961 1998-07-28 1999-07-28 Cellules genetiquement modifiees et tissus WO2000006204A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
KR1020017001189A KR20010085313A (ko) 1998-07-28 1999-07-28 유전자조작된 세포와 조직
EP99938808A EP1100548A2 (fr) 1998-07-28 1999-07-28 Cellules genetiquement modifiees et tissus
AU53212/99A AU5321299A (en) 1998-07-28 1999-07-28 Genetically engineered cells and tissues
JP2000562057A JP2002521046A (ja) 1998-07-28 1999-07-28 遺伝子工学的に操作された細胞および組織
CA002338487A CA2338487A1 (fr) 1998-07-28 1999-07-28 Cellules genetiquement modifiees et tissus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9440898P 1998-07-28 1998-07-28
US60/094,408 1998-07-28

Publications (2)

Publication Number Publication Date
WO2000006204A2 WO2000006204A2 (fr) 2000-02-10
WO2000006204A3 true WO2000006204A3 (fr) 2000-05-04

Family

ID=22245006

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/016961 WO2000006204A2 (fr) 1998-07-28 1999-07-28 Cellules genetiquement modifiees et tissus

Country Status (6)

Country Link
EP (1) EP1100548A2 (fr)
JP (1) JP2002521046A (fr)
KR (1) KR20010085313A (fr)
AU (1) AU5321299A (fr)
CA (1) CA2338487A1 (fr)
WO (1) WO2000006204A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846102B2 (en) 2006-03-30 2014-09-30 Engene, Inc. Non-viral compositions and methods for transfecting gut cells in vivo

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2403205A1 (fr) * 2000-03-13 2001-09-20 Engene, Inc. Compositions et methodes destinees a l'expression regulee d'une proteine dans l'intestin
DE10019195B4 (de) * 2000-04-17 2006-03-09 Heart Biosystems Gmbh Reversible Immortalisierung
KR101372966B1 (ko) * 2009-01-23 2014-03-13 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 표적 세포 유도용 피더 세포
JP6206792B2 (ja) * 2013-04-03 2017-10-04 誠一 横尾 培地及び細胞の培養方法
AU2019387218A1 (en) * 2018-11-26 2021-06-03 Massachusetts Institute Of Technology Compositions and methods for immune tolerance
CN114724643A (zh) * 2021-01-06 2022-07-08 腾讯科技（深圳）有限公司 一种多肽化合物的筛选方法以及相关装置

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995021927A2 (fr) * 1994-02-15 1995-08-17 Isis Innovation Limited Therapie genique de ciblage
WO1996040175A1 (fr) * 1995-06-07 1996-12-19 Advanced Tissue Sciences, Inc. Systeme de culture tridimensionnel base sur les cellules du stroma et destine a la formation de tubes, de tendons, de ligaments et de structures correctives
WO1998020041A1 (fr) * 1996-11-08 1998-05-14 Oklahoma Medical Research Foundation Expression specifique de l'endothelium regulee par des elements regulateurs du recepteur epcr
WO1999062562A1 (fr) * 1998-06-02 1999-12-09 University Of Washington Implant prothetique et techniques d'utilisation aux fins de l'expression de genes therapeutiques

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995021927A2 (fr) * 1994-02-15 1995-08-17 Isis Innovation Limited Therapie genique de ciblage
WO1996040175A1 (fr) * 1995-06-07 1996-12-19 Advanced Tissue Sciences, Inc. Systeme de culture tridimensionnel base sur les cellules du stroma et destine a la formation de tubes, de tendons, de ligaments et de structures correctives
WO1998020041A1 (fr) * 1996-11-08 1998-05-14 Oklahoma Medical Research Foundation Expression specifique de l'endothelium regulee par des elements regulateurs du recepteur epcr
WO1999062562A1 (fr) * 1998-06-02 1999-12-09 University Of Washington Implant prothetique et techniques d'utilisation aux fins de l'expression de genes therapeutiques

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846102B2 (en) 2006-03-30 2014-09-30 Engene, Inc. Non-viral compositions and methods for transfecting gut cells in vivo

Also Published As

Publication number Publication date
JP2002521046A (ja) 2002-07-16
WO2000006204A2 (fr) 2000-02-10
CA2338487A1 (fr) 2000-02-10
AU5321299A (en) 2000-02-21
EP1100548A2 (fr) 2001-05-23
KR20010085313A (ko) 2001-09-07

Similar Documents

Publication Publication Date Title
DE69637229T2 (de) Lipidisierung hydrophiler Moleküle
Girish et al. The magic glue hyaluronan and its eraser hyaluronidase: a biological overview
GEP20022804B (en) Erythropoietin Derivatives
WO2003006501A3 (fr) Conjugues de g-csf
NZ515476A (en) Conditioned cell culture medium compositions and methods of use
EP2422803A3 (fr) Compositions comprenant des cellules souches embryonnaires humaines et leurs dérivés, procédés d'utilisation et procédés de préparation
AU2002214596A1 (en) Methods and compositions for nucleic acid delivery
EP2236153A3 (fr) Composés et méthodes pour le traitement de maladies cardiaques
FI962154A (fi) Koostumus terapeuttisten tuotteiden in vivo valmistusta varten
AU2790292A (en) Viral recombinant vectors for expression in muscle cells
WO2004012759A3 (fr) Utilisation de l'erythropoietine
HK1014159A1 (en) Therapeutic uses of bactericidal/permeability-increasing protein dimer products
WO2003023000A3 (fr) Fragments d'adn lineaires destines a l'expression genetique
WO2005068498A3 (fr) Cellules therapeutiques humaines a secretion du facteur de croissance nerveuse
IL164817A (en) Composition comprising near diploid immortalized keratinocytes cells
WO2000006204A3 (fr) Cellules genetiquement modifiees et tissus
WO2003025167A3 (fr) Cellules de stroma cultivees et leurs utilisations
WO2023018990A3 (fr) Lipides pour l'administration d'acides nucléiques
MXPA04005204A (es) Derivados de hidrazonipirazol y su uso como terpapeuticos.
Khodabandeh et al. Effect of resistance exercise and liposomal vitamin C on some factors of mitochondrial dynamics and biogenesis
WO2003092598A3 (fr) Traitement contre la maladie de pompe
CA2441535A1 (fr) Techniques d'apport de molecules d'acides nucleiques dans des cellules et evaluation de cet apport
WO2001017563A3 (fr) Ciblage de medicament induit par l'integrine
WO2003099228A3 (fr) Compositions et procedes d'inhibition de l'expression genetique au moyen de polynucleotides
AU2001249267A1 (en) Methods and compositions for elucidating protein expression profiles in cells

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2338487

Country of ref document: CA

Ref country code: CA

Ref document number: 2338487

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 562057

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1020017001189

Country of ref document: KR

Ref document number: 53212/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 509672

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1999938808

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999938808

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020017001189

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1999938808

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1020017001189

Country of ref document: KR